Literature DB >> 16060666

Kinetic characterization of protein arginine deiminase 4: a transcriptional corepressor implicated in the onset and progression of rheumatoid arthritis.

Patricia L Kearney1, Monica Bhatia, Nelroy G Jones, Luo Yuan, Mary C Glascock, Kristen L Catchings, Michiyuki Yamada, Paul R Thompson.   

Abstract

Protein arginine deiminase 4 (PAD4) is a Ca(2+)-dependent enzyme that catalyzes the posttranslational conversion of arginine to citrulline (Arg --> Cit) in a number of proteins, including histones. While the gene encoding this enzyme has been implicated in the pathophysiology of rheumatoid arthritis (RA), little is known about its mechanism of catalysis, its in vivo role, or its role in the pathophysiology of RA; however, recent reports suggest that this enzyme can act as a transcriptional corepressor for the estrogen receptor. Herein, we report our initial kinetic and mechanistic characterization of human PAD4. Specifically, these studies confirm that PAD4 catalyzes the hydrolytic deimination of Arg residues to produce Cit and ammonia. The metal dependence of PAD4 has also been evaluated, and the results indicate that PAD4 activity is highly specific for calcium. Calcium activation of PAD4 catalysis exhibits positive cooperativity with K(0.5) values in the mid to high micromolar range. Evidence indicating that calcium binding causes a conformational change is also presented. Additionally, the steady-state kinetic parameters for a number of histone H4-based peptide substrates and benzoylated Arg derivatives have been determined. K(m) values for these compounds are in the high micromolar to the low millimolar range with k(cat) values ranging from 2.8 to 6.6 s(-)(1). The ability of PAD4 to catalyze the deimination of methylated Arg residues has also been evaluated, and the results indicate that these compounds are poor PAD4 substrates (V/K <or= 31.3 M(-)(1) s(-)(1)) in comparison to other substrates. These findings suggest that the full-length enzyme does not catalyze this reaction in vitro and possibly in vivo either. Collectively, the studies described herein will provide a firm foundation for the future development of PAD4 selective inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16060666     DOI: 10.1021/bi050292m

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  86 in total

1.  Citrullination of proteins: a common post-translational modification pathway induced by different nanoparticles in vitro and in vivo.

Authors:  Bashir M Mohamed; Navin K Verma; Anthony M Davies; Aoife McGowan; Kieran Crosbie-Staunton; Adriele Prina-Mello; Dermot Kelleher; Catherine H Botting; Corey P Causey; Paul R Thompson; Ger Jm Pruijn; Elena R Kisin; Alexey V Tkach; Anna A Shvedova; Yuri Volkov
Journal:  Nanomedicine (Lond)       Date:  2012-05-25       Impact factor: 5.307

2.  Photochemical Control of Protein Arginine Deiminase (PAD) Activity.

Authors:  Santanu Mondal; Sangram S Parelkar; Mitesh Nagar; Paul R Thompson
Journal:  ACS Chem Biol       Date:  2018-03-16       Impact factor: 5.100

3.  A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation.

Authors:  Yuan Luo; Bryan Knuckley; Young-Ho Lee; Michael R Stallcup; Paul R Thompson
Journal:  J Am Chem Soc       Date:  2006-02-01       Impact factor: 15.419

Review 4.  Protein arginine methyltransferases: from unicellular eukaryotes to humans.

Authors:  François Bachand
Journal:  Eukaryot Cell       Date:  2007-04-27

Review 5.  Protein Arginine Deiminases and Associated Citrullination: Physiological Functions and Diseases Associated with Dysregulation.

Authors:  Erin E Witalison; Paul R Thompson; Lorne J Hofseth
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

6.  The development of N-α-(2-carboxyl)benzoyl-N(5)-(2-fluoro-1-iminoethyl)-l-ornithine amide (o-F-amidine) and N-α-(2-carboxyl)benzoyl-N(5)-(2-chloro-1-iminoethyl)-l-ornithine amide (o-Cl-amidine) as second generation protein arginine deiminase (PAD) inhibitors.

Authors:  Corey P Causey; Justin E Jones; Jessica L Slack; Daisuke Kamei; Larry E Jones; Venkataraman Subramanian; Bryan Knuckley; Pedram Ebrahimi; Alexander A Chumanevich; Yuan Luo; Hiroshi Hashimoto; Mamoru Sato; Lorne J Hofseth; Paul R Thompson
Journal:  J Med Chem       Date:  2011-09-16       Impact factor: 7.446

7.  Seeing citrulline: development of a phenylglyoxal-based probe to visualize protein citrullination.

Authors:  Kevin L Bicker; Venkataraman Subramanian; Alexander A Chumanevich; Lorne J Hofseth; Paul R Thompson
Journal:  J Am Chem Soc       Date:  2012-10-03       Impact factor: 15.419

8.  Inactivation of epidermal growth factor by Porphyromonas gingivalis as a potential mechanism for periodontal tissue damage.

Authors:  Krzysztof Pyrc; Aleksandra Milewska; Tomasz Kantyka; Aneta Sroka; Katarzyna Maresz; Joanna Kozieł; Ky-Anh Nguyen; Jan J Enghild; Anders Dahl Knudsen; Jan Potempa
Journal:  Infect Immun       Date:  2012-10-22       Impact factor: 3.441

9.  Haloacetamidine-based inactivators of protein arginine deiminase 4 (PAD4): evidence that general acid catalysis promotes efficient inactivation.

Authors:  Bryan Knuckley; Corey P Causey; Perry J Pellechia; Paul F Cook; Paul R Thompson
Journal:  Chembiochem       Date:  2010-01-25       Impact factor: 3.164

10.  NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis.

Authors:  Ritika Khandpur; Carmelo Carmona-Rivera; Anuradha Vivekanandan-Giri; Alison Gizinski; Srilakshmi Yalavarthi; Jason S Knight; Sean Friday; Sam Li; Rajiv M Patel; Venkataraman Subramanian; Paul Thompson; Pojen Chen; David A Fox; Subramaniam Pennathur; Mariana J Kaplan
Journal:  Sci Transl Med       Date:  2013-03-27       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.